logo-loader
Collagen Solutions PLC

Collagen Sol PLC - Hardman Research: Engineering cartilage repairs

RNS Number : 2803Z
Collagen Solutions PLC
13 March 2017
 

Hardman Research: Engineering cartilage repairs

The link has been replaced following this morning's publication. We apologise for any inconvenience caused.

Engineering cartilage repairs: Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have been introduced over the last year to accelerate the rate of growth, including global commercial infrastructure and the development of a pipeline of finished medical devices. ChondroMimetic will be the first of these products and is expected to enhance significantly the value of the company which is not being reflected in the current share price. The recent capital raise and loan facility has resolved funding issues.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/collagen-solutions-plc-documents/cos-chondromimetic---13-march-2017.pdf

To contact us:

Hardman & Co

11/12 Tokenhouse Yard 

London

EC2R 7AS

Contacts:

Dr Martin Hall

mh@hardmanandco.com

Dr Dorothea Hill

dmh@hardmanandco.com

Dr Gregoire Pave

gp@hardmanabdco.com

Telephone: +44 20 7929 3399

Follow us on Twitter @HardmanandCo

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASFAFFDFWSEDD
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Morning Report: Vaccines and EU package lift FTSE 100

Headlines from the Proactive UK newsroom. The FTSE 100 was in better heart as yesterday’s vaccine news and €750bn EU bail-out package helped sentiment. The blue-chip index rose 43 points to 6,305. Grocery tills were their busiest ever over the past 12 weeks according to market research...

on 21/7/20

2 min read